Updates in Bowel Prep for 2022

Dr. Richard Sultanian, MD, MSc Associate Clinical Professor, University of Alberta Co-Medical Lead SCOPE Program January 21, 2023

BUNIVERSITY OF ALBERTA

Faculty/Presenter Disclosure

- Faculty: Dr. Richard Sultanian
- Relationships with commercial interests:
- Grants/Research Support: None
- Speakers Bureau/Honoraria: None
- Consulting Fees: None
- Other: Employee at the University of Alberta Hospital

EDMONTON-ALBERTA-CANADA

Objectives

- Review high level insights from the national B-CLEAN series of clinical trials on bowel preparation
 - Low volume vs. high volume split dose bowel preparation
 - Same day vs. split dose bowel prep
 - Day before vs. split dose bowel prep
- 2. Learn an evidence-based approach to failed bowel preparation
- 3. Gain knowledge of a new bowel preparation product recently available in Canada



Why does a good bowel preparation matter?

ALBERTA

Why does a good bowel preparation matter?

- Direct correlation with diagnostic accuracy and therapeutic safety of colonoscopy
- Adequate bowel preparation is an essential quality indicator for colonoscopy
- Inadequate bowel preparation leads to:
 - Higher complication rate
 - Incomplete colonoscopies
 - Decreased polyp detection (PDR) and adenoma detection rate (ADR)
 - Increased need to repeat/increase in cost

HIVERSITY OF EDMONTON-ALBERTA-CANADA

What are the clinically approved bowel preparation?


ALBERTA

What are the clinically approved bowel preparation?

- FDA Approved Bowel Preps:
 - PEG Based
 - Sodium picosulfate
 - Oral sulfate
- In Alberta approved provincial preparations:
 - PEG 4L (Colyte, Peglyte)
 - Sodium picosulfate (Picosalax)
 - Oral Sulfate (KleanLyte)
- PEG + bisacodyl (Bi-Peglyte)

EDMONTON-ALBERTA-CANADA

Provincial Standardized Prep Info



What is the optimal prep?

- Volume?
- Timing?
- Focus on PEG based preparations
- → B-CLEAN


BALBERTA EDMONTON-ALBERTA-CANADA


B-CLEAN

- The Bowel CLEAnsing A National Initiative (B-CLEAN) was a 10-centre nationwide 12-arm RCT aimed at answering multiple questions related to bowel preparation
 - University of British Columbia (Jennifer Telford)
 - University of Alberta (Richard Sultanian)
 - University of Calgary (Robert Hilsden)
 - University of Manitoba (Harminder Singh)
 - Western University (Michael Sey)
 - Ottawa University (Paul James) ÷.
 - McGill University (Alan Barkun) (Principal Investigator)
 - Université de Montréal (Daniel von Renteln)
 - Université Laval (Pierre Hallé) Dalhousie University (lan Epstein)

HIVERSITY OF

EDMONTON-ALBERTA-CANADA






OUTCOMES: TOLERABILITY


- Willingness to repeat preparation
- % of bowel preparation consumed
- Validated Bowel Preparation Tolerability Questionnaire¹


```
EDMONTON-ALBERTA-CANADA
```

1. Lawrence. Dig Dis Sci 2013;58:926-35.

PATIENT CHARACTERISTICS







	DW VOLUME DOSE	EFFICACY				
 2,314 patients randomized to: 1,157 to high volume split dose 2L PEG night before 		Variable	PegLyte Split-dose High-volume N=1,157	BiPegLyte Split-dose Low-volume N=1,157	p-value	
 2L PEG morning of procedure 	A REAL PROPERTY AND A REAL	Primary outcome				
 1,157 to low volume split dose 		Adequate*-no. (%)	966 (90.1%)	936 (88.1%)	0.02	
 15 mg bisacodyl 2 PM day before 		BBPS total score-mean (SD)	7.37±1.66	7.15±1.78	<0.01	
	a fill and	BBPS score right mean (SD)	2.37±0.64	2.31±0.66	0.02	
 1L PEG night before 		BBPS score transverse mean (SD)	2.51±0.61	2.44 ± 0.66	0.01	
 1L PEG morning of procedure 	Part of the	BBPS score left mean (SD)	2.48±0.63	2.37 ± 0.72	<0.01	
	THE KNOCK OUT					
		Adequate ≥5-no. (%)	1010 (94-9%)	985 (92.7%)	0.02	
	PegLyte pogLyte	Adequate ≥7-no. (%)	706 (66.4%)	663 (62.4%)	0.03	
ALBERTA	CRANPION VS PegLyte	WINIVERSITY OF ALBERTA		Barkun. Cli	n Gastroenterol He	epatol 2022;Online al
EDMONTON-ALBERTA-CANADA	*All boying references courtesy of Dr. M. Soul	EDMONTON-ALBERTA-CANADA				
DHORIORALDERIA-CARADA	*All boxing references courtesy of Dr. M. Sey!	COMONION-ALDENIA-CANADA				

	PegLyte	BiPegLyte		
Variable	Split-dose High-volume N=1,157	Split-dose Low-volume N=1,157	p-value	
Primery externe				Statistically
Adequate*-no. (%)	966 (90.1%)	936 (88.1%)	0.02	significant but
BBPS total score-mean (SD)	7.37±1.66	7.15±1.78	<0.01	perhaps not clinically meaningful
BBPS score right mean (SD)	2.37 ± 0.64	2.31±0.66	0.02	meaningfor
BBPS score transverse mean (SD)	2.51 ± 0.61	2.44 ± 0.66	0.01	
BBPS score left mean (SD)	2.48±0.63	2.37 ± 0.72	<0.01	
Adequate ≥5-no. (%)	1010 (94.9%)	985 (92.7%)	0.02	
Adequate ≥7-no. (%)	706 (66.4%)	663 (62.4%)	0.03	1


TOLERABILITY

Variable Split-dose High-volum Split-dose Low-volume Powhee Millingness to repart the preparation 6co (6c, 9t) Buck of Splits (co, 9t) Ausop Ausop Millingness to repart the preparation 6co (6c, 9t) Buck of Splits (co, 9t) Splits (co, 9t) Splits (co, 9t) Telements (bale of + sup (many triats) 21:131 Bitting Con Splits 20:010 21:010 Splits Con Splits 20:010 21:010 Ausop Splits Con Nexes 20:010 21:010 Ausop Splits Con Splits Con Nexes 20:010 21:010 Ausop Ausop Ausop Splits Con Ausop Au
Atograp Matage Willingness to repeat the preparation 6c2 (66.4) 951(52.7) co.0 Tolenance to repeat the preparation 6c2 (66.4) 951(52.7) co.0 Symptonic scale of a sol mean of 56d 2 + 2 + 3 8 + 1 + 5 co.0 Symptonic scale of a sol mean of 56d 2 + 2 + 3 8 + 1 + 5 co.0 Upplemeant table co.01 (1 + 49) -4 + (50.4) co.0 Naces x95 (16.69) x12 (1 - 29) co.0 Naces x95 (16.69) x12 (1 - 29) co.0 Absterinal pain - Comp x31 (1 - 89) y (1 + 29) co.0 Absterinal pain - Comp x31 (1 - 89) y (1 + 29) co.0 Distines x97 (1 + 99) x32 (1 + 29) co.0 Bedge tubance x97 (1 + 99) x14 (1 + 29) co.0 Bill Statubance x14 (1 + 79) x32 (1 + 49) co.0 Bill Statubance x45 (1 + 79) x32 (1 + 49) co.0 Bill Statubance x45 (1 + 79) x32 (1 + 49) co.0 Distines x32 (1 + 7
Willingsite is repeat the presention 622 (66,4%) Big (52,4%) 0.0.05 Symptoms 7.2.2.3 Bit 1.5 0.0.05 Symptoms 423 (10.2%) 42.2.2.3 Bit 1.5 0.0.05 Unplasant stands 423 (10.2%) 42.2.2.3 Bit 1.5 0.0.05 Excession third 100 (10.4%) 525 (10.4%) 0.0.05 0.0.05 Nancea 275 (10.4%) 521 (10.4%) 6.0.05 0.0
Telemance (scale of 2-sca) mass s/- 58d 2-2+3.1 8.11.9 <0.00.
Symptoms Operation Operation Locasion Birds 433 (16.15%) 435 (19.6%) 0.50 Locasion Birds 300 (16.4%) 751 (7.6%) 0.50 Natarea 205 (16.4%) 751 (7.6%) 0.50 Venting 6.5 (5.9%) 751 (7.6%) 0.50 Biseting 2.28 (5.9%) 751 (7.6%) 0.50 Abdeminal pain Comp 2.3 (18.0%) 0.50 (7.6%) 0.50 (7.6%) Difference 2.3 (18.0%) 0.50 (7.6%) 0.50 (7.6%) Steep distributions 345 (5.7%) 2.32 (18.0%) 0.50 (7.6%) Perinal instance 345 (5.7%) 2.32 (18.0%) 0.50 (7.6%) Chilts 323 (19.7%) 1.30 (18.0%) 0.50 (7.6%)
Unplasare tatat 4.31 (4.34) 4.52 (50.44) 0.50 Exercisive thirst 1.09 (0.44) 7.52 (4.34) 0.50 Nausa 5.75 (56.49) 3.22 (1.24) 0.00 Vorming 6.52 (59.4) 3.22 (1.24) 0.00 Bloating 2.82 (2.649) 3.24 (1.24) 0.00 Adominal pairs, Cramp 1.31 (2.649) 1.44 (1.2.49) 0.00 Bloating 2.92 (2.649) 1.29 (1.2.49) 0.00 Diazines 4.02 (9.34) 1.29 (1.2.49) 0.00 Diazines 4.02 (9.37) 1.29 (1.2.49) 0.00 Step directoranc 3.63 (5.74) 3.23 (1.0.49) 0.00 Oxilia 3.23 (10.74) 3.92 (10.74) 3.92 (10.74) 0.00
Excesse birst xxp(x,k) xp(x,k) xp(x,k) xxxx VemBig xxp(x,k) xxp(x,k) xxxx xxp(x,k) xxxx Bloating xxp(x,k) xxp(x,k) xxxx xxxx xxxx xxxx Abdominal pain - Camp xxp(x,k) xxxx xxx xx x xx xx
Nauce try (6.6%) try (1.4%) co.o. Vorming 65 (5%) 32 (5.0%)
Biologing 2 all (20 MH) 3 (4, 5), 2/M) -0 cm. Abdominal pains, Camp 331 (20 MH) 531 (20 MH) 501 (20 MH)
Abdominular Jain-Comp 131 (0.01%) 9,28 (5%) 0.08 Hoadsche 55 (14,9%) 131 (12,1%) 0.06 Dizziness 44 (15,9%) 36 (14,0%) 0.53 Steep diruthance 14 (15,9%) 124 (11,0%) 0.06 Preinal initation 129 (12,9%) 124 (11,0%) 0.06 Chilis 323 (15,9%) 134 (12,9%) 0.04
Headcole 12/14/24() 12/14/24() 0.06 Ditarines 0.10/24() 0.51/24() 0.52/24() 0.52/24() Step distubance 34/12/24() 0.52/24() 0.52/24() 0.52/24() 0.52/24() Perinal intraduce 34/12/24() 0.52/24()<
Dizzines: 41 (2 yH) 36 (4 xH) 0.53 Step detunded sk (15 yH) sk (15 yH) o.53 o.53 Perinal intution sk (15 yH) sk (15 yH
Steep disturbance 126 (157.9) 132 (12.99) -0.00 Perinal limitation 387 (12.99) 100 (00.93) -0.00 Chills 333 (10.79) 139 (17.99) -0.00 Compliance
Persianal initiation xb7 (57,9%) 100 (10.3%) <0.01
Chills 323 (30.7%) 191 (17.9%) <0.01
Compliance
100% compliance 781 (72.9%) 931 (84.9%) <0.01
85% compliance 938 (87.6%) 2046 (95.4%) <0.01
80% compliance 962 (89.8%) 1056 (96.3%) <0.01

TAKE HOME MESSAGE

- Split dose low volume PEG (BiPegLyte™) has comparable clinical efficacy to high volume split dose PEG (PegLyte™) but is much better tolerated
- Consider PegLyte[™] or BiPegLyte[™] as 1st line bowel preps





SPLIT DOSE VS. SAME DAY PREP

- 1,750 subjects randomized to: 583 to same day bowel prep
 15 mg bisacodyl 2 PM day before

 - 2L PEG morning of procedure
 585 to low volume split dose
 - 15 mg bisacodyl 2 PM day before
 - 1L PEG night before
 1L PEG morning of procedure
 - 582 to high volume split dose
 - 2L PEG night before
 2L PEG morning of procedure

HIVERSITY OF EDMONTON-ALBERTA-CANADA



		"Split dose 4L		plit dose BiPer	uLyte"	"Split dose 4L PEG or BiP	egLyte
Variable	"Same day pre Low-volume same-day	High-volume split-dose	Pvalue	Low-volume split-dose	Pvalue	Combined high-flow-volume split-dose	Pvalu
Primary outcome							
Adequate,* no. (%)	478 (90.5%)	495 (92.2%)	0.34	474 (87.9%)	0.17	969 (90.1%)	0.76
BBPS total score, mean (SD)	7.50 ± 1.70	7.44 ± 1.59	0.52	7.11 ± 1.78	<0.01	7.27 ± 1.69	0.01
BBPS score right, mean (SD)	2.45 ± 0.64	2.39 ± 0.62	0.12	2.30 ± 0.66	<0.01	2.34 ± 0.64	< 0.01
BBPS score transverse, mean (SD)	2.56 ± 0.62	2.53 ± 0.60	0.51	2.43 ± 0.66	< 0.01	2.48 ± 0.61	0.02
BBPS score left, mean (SD)	2.47 ± 0.68	2.52 ± 0.60	0.30	2.37 ± 0.70	<0.01	2.44 ± 0.66	0.3
Adequate ≥5, no. (%)	499 (94.5%)	517 (96.3%)	0.17	500 (92.8%)	0.24	1,017 (94.5%)	0.99
Adequate ≥7, no. (%)	379 (71.8%)	361 (67.2%)	0.11	337 (62.5%)	<0.01	698 (64.9%)	<0.01
BBPS, Boston Bowel Preparation Scale. "Defined as a BBPS cutoff of >6 with al		2				Barkun. Am J Gastoenterol 2023	;115;2068-
EDMONTON-ALBERTA-CANADA						76.	

EFFICACY

EFFICACY

		"Split dose 4L		plit dose BiPe	qLyte"	"Split dose 4L PEG or BiF	'egLyte'
Variable	"Same day pro Low-volume same-day	High-volume split-dose	Pvalue	Low-volume split-dose	Pvalue	Combined high-flow-volume split-dose	Pvalue
Primary outcome	5.000.000	concours:	STRUCT.	000000	antraines.		Construction of
Adequate,* no. (%)	478 (90.5%)	495 (92.2%)	0.34	474 (87.9%)	0.17	969 (90.1%)	0.76
BBPS total score, mean (SD)	7.50 ± 1.70	7.44 ± 1.59	0.52	7.11 ± 1.78	<0.01	7.27 ± 1.69	0.01
BBPS score right, mean (SD)	2.45 ± 0.64	2.39 ± 0.62	0.12	2.30 ± 0.66	<0.01	2.34 ± 0.64	< 0.01
BBPS score transverse, mean (SD)	2.56 ± 0.62	2.53 ± 0.60	0.51	2.43 ± 0.66	<0.01	2.48 ± 0.61	0.02
BBPS score left, mean (SD)	2.47 ± 0.68	2.52 ± 0.60	0.30	2.37 ± 0.70	<0.01	2.44 ± 0.66	0.36
Adequate ≥5, no. (%)	499 (94.5%)	517 (96.3%)	0.17	500 (92.8%)	0.24	1,017 (94.5%)	0.99
Adequate ≥7, no. (%)	379 (71.8%)	361 (67.2%)	0.11	337 (62.5%)	<0.01	698 (64.9%)	<0.01
BBPS, Boston Bowel Preparation Scale *Defined as a BBPS cutoff of #6 with a		-2.					
						Barkun. Am J Gastoenterol 202 76.	0;115;2068-

EDMONTON-ALBERTA-CANADA


EFFICACY

		"Split dose 4L		iplit dose BiPed	qLyte"	"Split dose 4L PEG or BiF	egLyte"
Variable	"Same day pre Low-volume same-day	ep" High-volume split-dose	Pvalue	Low-volume split-dose	Pvalue	Combined high-flow-volume split-dose	Pvalue
Primary outcome							
Adequate,* no. (%)	478 (90.5%)	495 (92.2%)	0.34	474 (87.9%)	0.17	969 (90.1%)	0.76
BBPS total score, mean (SD)	7.50 ± 1.70	7.44 ± 1.59	0.52	7.11 ± 1.78	<0.01	7.27 ± 1.69	0.01
BBPS score right, mean (SD)	2.45 ± 0.64	2.39 ± 0.62	0.12	2.30 ± 0.66	<0.01	2.34 ± 0.64	< 0.01
BBPS score transverse, mean (SD)	2.55 ± 0.62	2.53 ± 0.60	0.51	2.43 ± 0.66	< 0.01	2.48 ± 0.61	0.02
BBPS score left, mean (SD)	2.47 ± 0.68	2.52 ± 0.60	0.30	2.37 ± 0.70	<0.01	2.44 ± 0.66	0.36
Adequate ≥5, no. (%)	499 (94.5%)	517 (96.3%)	0.17	500 (92.8%)	0.24	1,017 (94.5%)	0.99
Adequate ≥7, no. (%)	379 (71.8%)	361 (67.2%)	0.11	337 (62.5%)	<0.01	698 (64.9%)	<0.01
BBPS, Boston Bowel Preparation Scale. *Defined as a BBPS cutoff of ≥6 with all		2					

Barkun. Am J Gastoenterol 2020;115;2068-76.



		"Split dose 4L		plit dose BiPe	gLyte"	"Split dose 4L PEG or BiP	'egLyte"
Variable	"Same day pro Low-volume same-day	P" High-volume split-dose	Pvalue	Low-volume split-dose	Pvalue	Combined high-/low-volume split-dose	Pvalue
Primary outcome							
Adequate,* no. (%)	478 (90.5%)	495 (92.2%)	0.34	474 (87.9%)	0.17	969 (90.1%)	0.76
BBPS total score, mean (SD)	7.50 ± 1.70	7.44 ± 1.59	0.52	7.11 ± 1.78	<0.01	7.27 ± 1.69	0.01
BBPS score right, mean (SD)	2.45 ± 0.64	2.39 ± 0.62	0.12	2.30 ± 0.66	<0.01	2.34 ± 0.64	< 0.01
BBPS score transverse, mean (SD)	2.56 ± 0.62	2.53 ± 0.60	0.51	2.43 ± 0.66	< 0.01	2.48 ± 0.61	0.02
BBPS score left, mean (SD)	2.47 ± 0.68	2.52 ± 0.60	0.30	2.37 ± 0.70	<0.01	2.44 ± 0.66	0.36
Adequate ≥5, no. (%)	499 (94.5%)	517 (96.3%)	0.17	500 (92.8%)	0.24	1,017 (94.5%)	0.99
Adequate ≥7, no. (%)	379 (71.8%)	361 (67.2%)	0.11	337 (62.5%)	<0.01	698 (64.9%)	< 0.01
BBPS, Boston Bowel Preparation Scale "Defined as a BBPS cutoff of ≈6 with a		-2.				Barkun. Am J Gastoenterol 2020 76	0;115;2068-



TOLERABILITY

Tariatio	Low-witume same-day	High-extense apiit doos	-	Lise solume aplit-dose	Pater.	Combined high-free- volume split-door	False
Willinghmut to repeat the preparation	645 (31,2%)	315-08.0%	<0.01	12220-005	0.40	771 (81.2%)	< 0.01
Research Incide of \$-328, mann it still	81+19	23+23	- =0.01	82519	0.65		=0.00
Synghole		In the second				3	
Unpinasarii briile	359 (29:9%)	223 (42.0%)	=0.05	198-06.7%	90.0	421 (39.3%)	0.05
Excessive third	3917.4%3	5019-453	0.23	32(5.9%)	0.54	8217.7%3	0.85
Nazza	54(10.2%)	72:03.0%)	0.10	6101.25	0.96	123 (12 4%)	0.20
Wanding	21 (8 0 %)	27.61%)	0.38	1412-653	0,10	41.03.893	0.84
Busing	11/19/02	307 000 2%4	=0.05	14123.8%	0.04	HE (17.0%)	
Abduminal pain-coamp	48 (5.1%)	56110.993	0.32	45(8.3%)	0.76	104 (9.7%)	0.68
Hadatha	89(23:2%)	97 (D8.2%)	0.02	70113.0%	0.09	167(33-8%)	037
Degrand	8(1.0%)	32(0.8%)	9.02	21 (4 75)	=0.01	43(40%)	= 0.01
Ship Solutions	47 (8.9%)	610165	0.15	49(0.1%)	0.09	130100.3%)	0.36
Peranal intolon	47(363%)	100-016-010	0.29	43(8,05)	+0.09	143(03.9%)	0.11
Chille	205(29/0%)	167-01.2%	<0.01	00126452	0.53	206-(24.9%)	0.00
Garglance							
Palaret lask the avegred preparation	532(198,2%)	129 (96.2%)	0.96	103 (99.3%)	0.10	1.0%2 (98.7%)	0.36
Patient respected the assigned det	500 553-8% (515-095.6%	0.20	\$14/04.3%	0.73	1.029 (94.9%)	0.35
100% constance*	472/87.7%3	257 (71.8%)	<0.01	400.00.3%	0.49	9877 (983 276.)	<0.01
80% compliance	400 (92.8%)	475-000.3%3	0.01	120.00102	0.03	1.008/92.2%)	0.66
RPS compliance	100103-014	409.00751	0.08	107 196,011	0.02	1025288.7%	0.88
75% consistents	321 (M.RN)	101 (83 7%)	0.02	541 (97 141	0.65	1.045 (95.5%)	0.20
Since to the end of the land done to coloresticage	38±20	45922	<0.01	30 c 23	=0.00	48122	=0.00

TAKE HOME MESSAGE

- Same day prep is roughly equivalent to low volume split dose and high volume split dose in achieving adequate bowel prep
- Same day prep and high volume split dose may be a bit better at achieving a cleaner colon beyond 'adequate'
- Same day and low volume split dose bowel preps are better tolerated than high volume split dose prep


EDMONTON ALBERTA-CANADA



<section-header><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item>

	Day before high-volume N=579	Split-dose high-volume N=575	p-value	Split-dose low-volume N=572	p-value	(High or Low) split- dose N=1147	p-value
BBPS Adequate*	71.8%	89.4%	\$0.001	88.2%	60.001	88.8%	<u><0.001</u>
Total BBPS	6.2 ± 2.0	7.3 ± 1.7	<0.001	7.2 ± 1.8	<0.001	7.2 ± 1.8	<0.001
Boston 2 7	42.9%	65.5%	<u><0.001</u>	66.2%	<0.001	63.8%	<u><0.001</u>
Patient willing to repeat the preparation	59.6%	64.8%	0.107	91.2%	<u><0.001</u>	78.5%	<u><0.001</u>
Patient Tolerance (1-10 scale)	7.0 ± 2.3	7.2 ± 2.4	0.106	8.0±1.8	<u> <0.001</u>	7.6±2.1	<u>×0.001</u>


TOLERABILITY



TAKE HOME MESSAGE

- Split dose bowel prep results in a cleaner colon and better patient tolerability
- There is little role for 4L day before bowel prep as a first line agent in routine outpatient colonoscopy

EDMONTON-ALBERTA-CANADA



EDMONTON-ALBERTA-CANADA

B-CLEAN Conclusion

 Same-day low-volume PEG (2L) compared split-dose highvolume PEG (2L+2L) and/or split-dose low-volume (1L+1L) PEG with bisacodyl (15mg)

- Low volume PEG given the day of the colonoscopy independent of diet (clear liquid or low residue)
- Similar bowel cleanliness compared to split-dose high-volume PEG
- Better bowel cleanliness compared to split-dose low volume PEG
- Same-day low-volume PEG
- Greater willingness-to-repeat compared to split-dose high-volume PEG
- No different willingness-to-repeat compared to split-dose lowvolume PEG

EDMONTON-ALBERTA-CANADA

B-CLEAN Conclusion

- <u>Day before</u> high-volume PEG (4L) versus split-dose high-volume PEG (2L+2L) and/or split-dose low-volume PEG (1L+1L) with Bisacodyl (15mg)
- Day before high-volume PEG independent of diet (clear liquid or low residue)
- Worse bowel cleanliness compared to split-dose high volume PEG
- Worse bowel cleanliness compared to split-dose low volume PEG
- Lower patient willingness to repeat compared to the split-dose low-volume PEG
- Not significantly different patient willingness to repeat compared to the split-dose high-volume PEG
- Inferior cecal intubation and polyp detection vs split-dose highvolume PEG

EDMONTON-ALBERTA-CANADA



WHAT ABOUT FAILED BOWEL PREP?

ALBERTA

WHAT ABOUT FAILED BOWEL PREP?

- The <u>Bowel CLEAn</u>sing: A <u>National Initiative</u> -<u>Repeat Colonscopy</u> (B-CLEAN(R) was a 4-centre RCT comparing two regimens for use after an initial failed attempt at bowel preparation
 - University of Alberta (Richard Sultanian)
 - Western University (Michael Sey) (Principal Investigator)
 - McGill University (Alan Barkun)
 - Université de Montréal (Daniel von Renteln)

ALBERTA DMONTON-ALBERTA-CANADA

ELIGIBILITY CRITERIA: B-CLEAN(R)

- Inclusion criteria
 - Anyone who failed outpatient on label bowel preparation requiring a repeat colonoscopy
- Exclusion criteria
 - Non-compliance with index bowel preparation
 - Intolerance to PEG based bowel prep
 - Used off-label bowel preparation
 - Inpatient index colonoscopy
 - Increased risk for fluid/electrolyte disturbances

EDMONTON-ALBERTA-CANADA

RANDOMIZATION: B-CLEAN(R)

- Regimen A
 - 15 mg bisacodyl at 2 PM the day before colonoscopy
 - 2L PegLyte the night before colonoscopy
 - 2L PeqLyte the morning of colonoscopy
- Regimen B
 - 15 mg bisacodyl at 2 PM the day before colonoscopy
 - 4L PegLyte the night before colonoscopy
- 2L PegLyte the morning of colonoscopy
 Both preceded by a low fiber diet 3 and 2 days before colonoscopy and clear fluids day before and day of the procedure

EDMONTON-ALBERTA-CANADA

RANDOMIZATION: B-CLEAN(R)

- Regimen A
- 15 mg bisacodyl at 2 PM the day before colonoscopy
- 2L PegLyte the night before colonoscopy or PegLyte 4+ 15mg bisacodi
- 2L PeqLyte the morning of colonoscopy
- Regimen B
 - 15 mg bisacodyl at 2 PM the day before colonoscopy
 - 4L PegLyte the night before colonoscopy
- 2L PegLyte the morning of colonoscopy
 Both preceded by a low fiber diet 3 and 2 days before colonoscopy and clear fluids day before and day of the procedure

EDMONTON-ALBERTA-CANADA

RANDOMIZATION: B-CLEAN(R)

Regimen A

- 15 mg bisacodyl at 2 PM the day before colonoscopy = RF ad us 2 boxes 15 mg bisacody
- 15 mg Disacouyi at 2 Five the day before colonoscopy or 2L PegLyte the night before colonoscopy or PegLyte 4L+15 mg bisacodyi
- 2L PegLyte the morning of colonoscopy
 <u>Regimen B</u>
- - 15 mg bisacodyl at 2 PM the day before colonoscopy
- 4L PegLyte the night before colonoscopy
- 2L PegLyte the morning of colonoscopy
 Both preceded by a low fiber diet 3 and 2 days before colonoscopy and clear fluids day before and day of the procedure

EDMONTON-ALBERTA-CANADA

TABLE 1: PATIENT **CHARACTERISTICS**

		. PEL2 (/, research) (- N).	PEE 4 - 21, - 246 and 42 (1 - 248	
	Nam J. Frendt (1923	101.0.011.01	#6.8.918	
	Partyle - 2 This	M-41-5.	41040	
	MAL > FILE Instance and pro- fearming Charl anough Charles Machinely, disease	+0.1 10,00.0 11,00.0 11,00.0 12,00	13.0 pr.014 pr.014 pr.014 pr.014 pr.014	
	Minus) Broginge, 1-(N) Tropies Frankt Office	1.420 1.420	10.00.6 (2.00.6 (2.00.6	
	Regime and of associate, in Fig. Loss Part Regimented Status Undergraduate regimeter Disability of publication Status for an annual Matter for an annual	1000.0 1000.0 1000.0 1000.0 1000.0	9-935 9-965 9-962 9-962 9-962	
	Darwer zweinisch nich + Hr - 5 - 54 - 54 - 7	100	1.014 16.018 1.018	
	Constantion failures of PES	10.004	19.00.0	
	tribalite lactored spinoletring, constrained adultation, Restrict, 4 (792)	100	19.758	
	Marchaley bond durate limites, e (%)	4.8.7%	4.94/%	
	Programmy of addressal surgery in the	11' 100 b	26.66.5	
	Restaurden von 100 Neuronen Konsteinungen Carlon och erstellter Order och	111	111	
	Annue property and the set of the	10.0040 41.002 11.012 41.02 11.012 41.012 11.012 11.012	81.954 96.954 959 959 959 959 959 959 959 959	
N=196	Bagrante Baserie de collecte construite	127	111	
ALBERTA				Sey. Clin Gastroenterol Hepatol 2022: Online ahead print
DMONTON-ALBERTA-CANADA				

EFFICACY

	PEG 2+2L+bisacodyl (n = 97)	PEG 4+2L+bisacodyl (n = 99)	RR (95% CI)	P valu
Adequate preparation, n (%) BBPS definition USMSTF definition	83 (91.2) 82 (91.1)	78 (87.6) 76 (85.4)	0.96 (0.87-1.06) 0.94 (0.85-1.04)	.44 .24
BBPS, median (IQR) Total score Right colon Transverse colon Left colon	7 (6-0) 2 (2-3) 2 (2-3) 2 (2-3)	7 (6-9) 2 (2-3) 2 (2-3) 3 (2-3)	-	.95 .33 .51 .56
Detection rates, n (%) Adenoma Advanced adenoma Sessile serrated lesion Polyp Adenoma/colonoscopy Polyp/colonoscopy	34 (37.4) 17 (18.7) 8 (8.0) 53 (58.2) 0.99 (1.88) 1.54 (2.29)	28 (31.5) 10 (11.2) 5 (5.6) 49 (55.1) 0.64 (1.15) 1.25 (1.33)	0.84 (0.56-1.26) 0.79 (0.55-1.13) 0.64 (0.22-1.88) 0.94 (0.73-1.22)	.41 .19 .41 .66 .13 .36
Cecal intubation, n (%)	87 (96.7)	82 (92.1)	0.95 (0.89-1.02)	.19

EFFICACY PEG 2+2L+bisacodyl (n = 97) PEG 4+2L+bisacodyl (n = 99) RR (95% Cl) P value 83 (91.2) 82 (91.1) 0.96 (0.87-1.06) .44 .24 78 (87.6) 76 (85.4) 7 (6-9) 2 (2-3) 2 (2-3) 2 (2-3) 2 (2-3) 7 (6-9) 2 (2-3) 2 (2-3) 3 (2-3) .95 .33 .51 .56 34 (37.4) 17 (18.7) 8 (8.8) 53 (58.2) 0.99 (1.88) 1.54 (2.29) 28 (31.5) 10 (11.2) 5 (5.6) 49 (55.1) 0.64 (1.15) 1.25 (1.93) 0.84 (0.56-1.26) 0.79 (0.55-1.13) 0.64 (0.22-1.88) 0.94 (0.73-1.22) .41 .19 .41 .66 .13 .36 tubation, n (%) 87 (96.7) 82 (92.1) 0.95 (0.89-1.02) .19 Sey. Clin Gast print HIVERSITY OF ALBERTA EDMONTON-ALBERTA-CANADA

EFFICACY

	PEG 2+2L+bisacodyl (n = 97)	PEG 4+2L+bisacodyl (n = 99)	RR (95% CI)	P valu
Adequate preparation, n (%)				
BBPS definition USMSTF definition	83 (91.2) 82 (91.1)	78 (87.6) 76 (85.4)	0.96 (0.87-1.06) 0.94 (0.85-1.04)	.44
BBPS, median 80R)				
Total score	7 (5-9)	7 (6-9)	-	.95
Right colon	2 (2-3)	2 (2-3)	-	.95
Transverse colon	2 (2-3)	2 (2-3)	-	.51
Left colon	2 (2-3)	3 (2-3)	-	.56
Detection rates, n (%)				
Adenoma	34 (37.4)	28 (31.5)	0.84 (0.56-1.26)	.41
Advanced adenoma	17 (18.7)	10 (11.2)	0.79 (0.55-1.13)	.19
Sessile serrated lesion	8 (8.8)	5 (5.6)	0.64 (0.22-1.88)	
Polyp	53 (58.2)	49 (55.1)	0.94 (0.73-1.22)	.66
Adenoma/colonoscopy	0.99 (1.88)	0.64 (1.15)	-	.13
Polyp/colonoscopy	1.54 (2.29)	1.25 (1.93)	-	.36
Cecal intubation, n (%)	87 (96.7)	82 (92.1)	0.95 (0.89-1.02)	.19
VERSITY OF		Sey.	Clin Gastroenterol Hep	atol 2022:C

EFFICACY

	PEG 2+2L+bisacodyl (n = 97)	PEG 4+2L+bisacodyl (n = 99)	RR (95% CI)	P valu
Adequate preparation, n (%) BBPS definition USMSTF definition	83 (91.2) 82 (91.1)	78 (87.6) 76 (85.4)	0.96 (0.87-1.06) 0.94 (0.85-1.04)	.44 .24
BBPS, median (IQR) Total score Right colon Transvense colon Left colon	7 (6-9) 2 (2-3) 2 (2-3) 2 (2-3)	7 (6-6) 2 (2-3) 2 (2-3) 3 (2-3)	-	.95 .33 .51 .56
Detection rates, n (%) Adenoma Advanced adenoma Sessile serrated lesion Polyp Adenoma/colonoscopy Polyp/colonoscopy	34 (37.4) 17 (18.7) 8 (8.0) 53 (56.2) 0.99 (1.88) 1.54 (2.28)	28 (31.5) 10 (11.2) 5 (5.6) 49 (55.1) 0.64 (1.15) 1.25 (1.93)	0.84 (0.56-1.26) 0.79 (0.55-1.13) 0.64 (0.22-1.88) 0.94 (0.71-1.22)	,41 ,19 ,41 ,66 ,13 ,36
Cecal intubation, n (%)	87 (96.7)	82 (92.1)	0.95 (0.89-1.02)	.19

	PEG 2+2L+breacodyl (n = 97)	PEG 4+2L+binacodyl (n = 99)	Proto
Adherence to det, n (%) Low liber det portion Dear fait det sonton	78.592.05 80.056.41	79.64.0 81.66.0	78
Afterence to purplice, n (%)			
PEG. 1075 all-rent	75 (94.7)	42.04.0	30 (1)
PEG, 80% advered	75 (MLZ) 79 (MLR)	80 (29.5)	01
Overal adherence Diet + purperive, 100%	47.81.7)	53 66 0	05
Det - purgative, 80%	71.0640	57 (73.1)	.05
PEG ingested, median (OP)	4 (4-4)	68-0	-1.0001
Tolerability components," median (KDP) Unpleasant tester	20-3	20.4	at
Excassive thrst	0.0-0	0.61-13	.25
Nausea	0.0-21	00-0	-54
Vointing	0.0-0	0.0-0)	.58
Bloating Abdorrand cramps	0.0-0	16-3	.00 .07
Abdommul cramps Headaches	1.0-0	0.0-0	
Distriment	00-0	00-0	
Since disturbance	0.0-2	0.0-3	08
Peri-anal initiation	0.0-2	10-0	.15
CHIN	1.0-3	10-3	.74
Appreprise tolerability score	6 (3-12)	8 (3-12)	.38
Tolerability visual analogue scale," median (OP)	76-8	80-6	
Fecal incontinence	11.03.0	12/04/8	.82
Willingness to repeat toower preparation Yes	42.012	49.051.0	<.001
745	6.8.8	25 03.8	



